Showing results (81-90 of 115) with videos related to
Sort By:
Pageof 12
Blood|December 3, 2021
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccinationYair Herishanu, Galia Rahav, Shai Levi, et al.American Journal of Hematology|August 12, 2014
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study GroupTamar Tadmor, Lev Shvidel, Osnat Bairey, et al.Anticancer Research|February 11, 2014
Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study groupTamar Tadmor, Lev Shvidel, Neta Goldschmidt, et al.Hematological Oncology|February 14, 2019
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experienceYair Herishanu, Tamar Tadmor, Andrei Braester, et al.Haematologica|February 10, 2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experienceYair Herishanu, Neta Goldschmidt, Osnat Bairey, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 18, 2012
Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progressionYair Herishanu, Sigi Kay, Nili Dezorella, et al.Leukemia Research|February 26, 2014
Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrationsYair Herishanu, Sigi Kay, Erel Joffe, et al.European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.Hematological Oncology|October 30, 2016
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patientsRaffaella Marcheselli, Alessia Bari, Tamar Tadmor, et al.Hematological Oncology|June 23, 2017
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survivalErel Joffe, N Ariela Arad, Osnat Bairey, et al.Pageof 12